Clinical trials: in Panama
Norovirus
Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Children
The purpose of this study is to select the optimal formulation of the norovirus vaccine from different concentrations of virus-like particles (VLP) combined with aluminum hydroxide for further development in children.
- Trial name
- NCT02153112
- Testing
- GI.1/GII.4 (15/15), GI.1/GII.4 (15/50), GI.1/GII.4 (50/50)
- Where
- 12 sites in Colombia, Finland and 1 more
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Takeda
Infections, Meningococcal
Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds
The purpose of the observer-blinded study is to determine the immunogenicity and safety of one dose of GlaxoSmithKline (GSK) Biologicals' meningococcal vaccine GSK 134612 compared to one dose of Mencevax™ ACWY in healthy subjects…
- Trial name
- NCT01154088
- Testing
- Mencevax ACWY, GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]
- Where
- 3 sites in Panama, Philippines and 1 more
- Volunteers
- 1,170 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis
Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age
The trial is a phase III, non-inferiority, observer-blind, randomised, active controlled, multicentre clinical trial with 2 parallel groups: IPV-Al SSI (investigational vaccine) and IPV SSI (comparator vaccine).
- Trial name
- VIPV-07 (NCT03025750)
- Testing
- IPV-Al SSI, IPV SSI
- Where
- Panama
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Poliomyelitis
Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months
This is a phase III assessing the safety and immunogenicity of adjuvanted the reduced dose inactivated polio vaccine, IPV-Al SSI given as a booster vaccination to infants who were previously immunised with primary vaccination of…
- Trial name
- NCT03671616
- Testing
- IPV-Al SSI
- Where
- Panama
- Volunteers
- 666 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Respiratory Syncytial Virus Infections
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants
The purpose of this study was to evaluate the efficacy, safety, pharmacokinetics (PK), and immunogenicity of suptavumab (REGN2222) in infants born no more than 35 weeks, 6 days gestational age who are no more than 6 months of age…
- Trial name
- NCT02325791
- Testing
- Suptavumab 30 mg/kg, Suptavumab 30 mg/kg- 1 Dose, Suptavumab 30 mg/kg - 2 Doses
- Where
- 205 sites in United States, Australia and 17 more
- Volunteers
- 1,177 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
Influenza
A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children
This study is designed to test the efficacy of an investigational influenza vaccine, in children compared to Havrix®, a licensed Hepatitis A virus vaccine.
- Trial name
- NCT01218308
- Testing
- FluLaval® Quadrivalent, Havrix™
- Where
- 12 sites in Bangladesh, Dominican Republic and 6 more
- Volunteers
- 5,220 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Intraocular Pressure
Eyenovia MiDD Usability Study
This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)
- Trial name
- NCT03480906
- Testing
- Latanoprost
- Where
- Panama
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eyenovia Inc.
Infections, Rotavirus
To Assess Immunogenicity, Reactogenicity & Safety of 2 Formulations of GSK's HRV Vaccine as 2-dose Vaccination (Infants)
This trial will be conducted to evaluate the immunogenicity, reactogenicity and safety of the liquid formulation of GSK Biologicals' HRV vaccine compared to the lyophilized formulation of GSK Biologicals' HRV vaccine
- Trial name
- NCT00363545
- Testing
- Lyophilized formulation of HRV vaccine, Liquid formulation of HRV vaccine
- Where
- 3 sites in Panama
- Volunteers
- 1,274 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Spinal Cord Injury
Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury
Human Umbilical Cord-derived Mesenchymal Stem Cells (UC-MSC) and Bone Marrow Mononuclear Cells (BMMC) from the patient injected into the spinal fluid intrathecally and injected intravenously (IV) is a safe and therapeutic…
- Trial name
- NCT02237547
- Testing
- Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells
- Where
- Panama
- Volunteers
- healthy volunteers welcome
- Sponsor
- Translational Biosciences
Infections, Papillomavirus
Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.
Human Papilloma virus (HPV) are viruses that cause a common infection of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the…
- Trial name
- NCT00196924
- Testing
- HPV-16/18 L1/AS04
- Where
- 61 sites in Australia, Colombia and 10 more
- Volunteers
- 2,067 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Post Partum Severe Preeclampsia
Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia
There is no evidence that patients receiving magnesium sulfate before birth are required to maintain the drug for 24 hours. Therefore the investigators will have a randomized clinical study in patients with severe preeclampsia…
- Trial name
- MAG-PIP (NCT02307201)
- Testing
- Magnesium Sulfate
- Where
- 9 sites in Dominican Republic, Ecuador and 3 more
- Volunteers
- 1,114 people, healthy volunteers welcome
- Sponsor
- Complejo Hospitalario Dr. Arnulfo Arias Madrid
Severe Pre-eclampsia With Postnatal Complication
Magnesium Sulfate in Pregnancy and Postpartum
There are huge doubts as to how long to keep postpartum magnesium sulfate. Studies demonstrating the usefulness for 24, 12 or 6 hours are of little evidence and do not take into account the use of magnesium sulphate before…
- Trial name
- MAG-PP (NCT02317146)
- Testing
- Magnesium Sulfate
- Where
- 3 sites in Panama
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Complejo Hospitalario Dr. Arnulfo Arias Madrid
Infections, Rotavirus
Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants
The main objectives of this study is to determine vaccine efficacy against severe rotavirus (RV) gastroenteritis (GE) during the period starting from 2 weeks after Dose 2 until one year of age.
- Trial name
- NCT00139347
- Testing
- 2-dose oral live attenuated G1P[8] human rotavirus vaccine
- Where
- 17 sites in Argentina, Brazil and 4 more
- Volunteers
- 6,360 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tinea Corporis
Pediatric Subjects With Tinea Corporis
The study is being done to see how well the study cream works when applied once a day to affected area of child (where they have ringworm).
- Trial name
- NCT02227290
- Testing
- Naftin Cream
- Where
- 19 sites in United States, Dominican Republic and 3 more
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Merz North America, Inc.
Infections, Streptococcal
Healthcare Seeking Behaviour of Primary Caregivers for Acute Otitis Media (AOM) in Children Aged 6 Months to Less Than 30 Months in Panama
The study is a survey aiming to describe the healthcare seeking behaviour of primary caregivers when their child aged 6 months to less than 30 months was suspected to have an episode of acute otitis media in Panama.
- Trial name
- NCT01793857
- Testing
- Data collection
- Where
- 13 sites in Panama
- Volunteers
- 1,330 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis
Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine
This study is a Phase IV, open, randomized, multi-center, controlled vaccine trial conducted in healthy Latin American infants, utilizing one or two supplemental doses of IPV in children previously vaccinated with 3 doses of…
- Trial name
- NCT01831050
- Testing
- Bivalent Oral Polio Vaccine (bOPV), Trivalent Oral Polio Vaccine (tOPV), Monovalent Oral Polio Vaccine Type 2 (mOPV2)
- Where
- 4 sites in Colombia, Dominican Republic and 2 more
- Volunteers
- 1,420 people, healthy volunteers welcome
- Sponsor
- Fidec Corporation
Hypertension
Nonsteroidal Antiinflammatory Drugs in Women With Postpartum Pre-eclampsia
Hypertensive disorders of pregnancy are a major cause of maternal mortality and morbidity, especially in developing countries. Postpartum hypertension can be related to persistence of gestational hypertension, preeclampsia, or…
- Trial name
- NCT01988298
- Testing
- Ibuprofen, Acetaminophen
- Where
- Panama
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Complejo Hospitalario Dr. Arnulfo Arias Madrid
Polio
Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life
Phase II, observer-blind, randomized study on the safety, reactogenicity, immunogenicity and impact on intestinal shedding of a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD) or a single…
- Trial name
- IPV005 (NCT02111135)
- Testing
- b-OPV, m-OPV2, m-IPV HD
- Where
- Panama
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Vaxtrials S.A.
Meningococcal Disease, Meningococcal Meningitis
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines
This study will evaluate safety, tolerability, and immunogenicity of a booster dose of a meningococcal vaccine formulation in adolescents.
- Trial name
- NCT01367158
- Testing
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Tdap
- Where
- 7 sites in Chile, Colombia and 1 more
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects
The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing process of three consecutive lots of…
- Trial name
- NCT01162122
- Testing
- MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV)
- Where
- 38 sites in United States, Colombia and 2 more
- Volunteers
- 7,109 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines